Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check29 days agoChange DetectedThe page has been updated to indicate that results have been submitted, replacing the previous message that no results were posted.SummaryDifference0.1%
- Check36 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a clinical study on efgartigimod for post-COVID-19 postural orthostatic tachycardia syndrome (POTS) and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference35%
- Check43 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check87 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check101 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.